Final Agenda
18th meeting of the Committee for Risk Assessment
26 – 28 October 2011
Helsinki, Finland
26 October: starts at 9:00
28 October: ends at 14:00

Item 1 – Welcome & Apologies

Item 2 – Adoption of the Agenda
RAC/A/18/2011 Rev. 1
For adoption

Item 3 – Declarations of conflicts of interest to the Agenda

Item 4 – Adoption of the minutes of the RAC-17
RAC/M/17/2011
For adoption

Item 5 – Administrative issues and information items

5.1 Status report on the RAC-17 action points
5.2 Outcome of written procedures
5.3 Report from other ECHA bodies and activities
   - Report on MB policy of handling of conflict of interest
RAC/18/2011/28
For information
6.1 Gallium arsenide

For discussion and possible adoption

7.1 CLH Dossiers for discussion and possible adoption

a. N-ethyl-2-pyrrolidone (NEP)

b. Ammoniumpentadecafluorooctanoate (APFO)

c. Perfluoroctanic acid (PFOA) and its salts

d. Sulcotrione

e. Nitrobenzene

f. Penconazole

g. Ethylbenzene

h. Octadecylamine

i. (Z)-octadec-9-enylamine

j. Amines, hydrogenated tallow alkyl

k. Amines, coco alkyl

l. Amines, Tallow alkyl

7.2 CLH Dossiers for first discussion

m. Aluminium phosphide

n. Trimagnesium diphosphide
7.3 **Appointment of RAC (co-) rapporteurs for CLH dossiers**
   a. Appointment of RAC (co-) rapporteurs for CLH dossiers
      
      \[\text{RAC/18/2011/29} \]
      \[\text{room document} \]
      \[\text{For agreement} \]

7.4 **General CLH issues**
   a. State of play of the submitted CLH dossiers
      
      \[\text{RAC/18/2011/26} \]
      \[\text{For information} \]
   b. Review of the process for developing CLH opinions
      
      \[\text{RAC/18/2011/33} \]
      \[\text{room document} \]
      \[\text{For information} \]

<table>
<thead>
<tr>
<th>Item 8 – Restrictions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8.1 Restriction Annex XV dossiers</strong></td>
</tr>
<tr>
<td>a. Update on the Phthalates dossier</td>
</tr>
<tr>
<td><strong>8.2 General restriction issues (if relevant)</strong></td>
</tr>
<tr>
<td>a. Update on intended restriction dossiers</td>
</tr>
<tr>
<td><strong>8.3 Appointment of RAC (co-) rapporteurs for restrictions dossiers</strong></td>
</tr>
</tbody>
</table>
| \[\text{RAC/18/2011/30} \]
| \[\text{room document} \]
| \[\text{For agreement} \]

<table>
<thead>
<tr>
<th>Item 9 – Authorisation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>9.1 Appointment of RAC rapporteurs for substances listed in Annex XIV (if relevant)</strong></td>
</tr>
</tbody>
</table>
| \[\text{RAC/18/2011/31} \]
| \[\text{room document} \]
| \[\text{For agreement} \]
| **9.2 General authorisation issues (if relevant)** |

<table>
<thead>
<tr>
<th>Item 10 – Guidance issues</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10.1 Feedback from guidance consultations</strong></td>
</tr>
<tr>
<td><strong>10.2 Report on other guidance activities</strong></td>
</tr>
</tbody>
</table>
| \[\text{RAC/18/2011/27} \]
| \[\text{For information} \]

| Item 11 – Update on stakeholder participation in the work of RAC |
Item 12 – Any other business

Item 13 – Main conclusions and Action Points of RAC-18

Table with main conclusions and action points from RAC-18

For adoption

PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-18
Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

Some discussions may require a closed session

Wednesday, 26 October: Morning Session

Item 1 – Welcome & Apologies
Item 2 – Adoption of the Agenda
Item 3 – Declarations of conflicts of interest to the Agenda
Item 4 – Adoption of the minutes of the RAC-17
Item 5 – Administrative issues and information items
  5.1 Status report on the RAC-17 action points
  5.2 Outcome of written procedures
  5.3 Report from other ECHA bodies and activities
    - Report on MB policy of handling of conflict of interest
Item 8 – Restrictions
  8.1 Restriction Annex XV dossiers
    a. Update on the Phthalates dossier (short presentation by rapporteurs)
  8.2 General restriction issues (if relevant)
    b. Update on intended restriction dossiers
Item 9 – Authorisation
  9.2 General authorisation issues (if relevant)
Item 11 – Update on stakeholder participation in the work of RAC (Closed Session)
Item 7 – CLH
  7.1 CLH Dossiers for discussion and possible adoption
    h. Octadecylamine
    i. (Z)-octadec-9-enylamine
    j. Amines, hydrogenated tallow alkyl
    k. Amines, coco alkyl
    l. Amines, Tallow alkyl
Wednesday, 26 October: Afternoon Session
Item 7 – CLH

7.1 CLH Dossiers for discussion and possible adoption
   g. Ethylbenzene
   f. Penconazole

7.2 CLH Dossiers for first discussion
   m. Aluminium phosphide
   n. Trimagnesium diphosphide

Optional – 7.1 CLH Dossiers for discussion and possible adoption: second discussion on CLH dossiers for adoption as needed.

Thursday 27 October: Morning Session
Item 7 – CLH

7.1 CLH Dossiers for discussion and possible adoption (cont.)
   d. Sulcotrione
   e. Nitrobenzene

Item 6 – Requests under Article 77 (3)(c)
   6.1 Gallium arsenide

Optional – 7.1 CLH Dossiers for discussion and possible adoption: continuation of discussion on CLH dossiers for adoption as needed.
Optional – 7.2 CLH Dossiers for discussion: continuation of discussion on CLH dossiers as needed.

Thursday 27 October: Afternoon Session
Optional – Item 6 – Requests under Article 77 (3)(c) continuation of discussion if needed
   6.1 Gallium arsenide

Optional – 7.1 CLH Dossiers for discussion and possible adoption: continuation of discussion on CLH dossiers for adoption as needed.
Optional – 7.2 CLH Dossiers for discussion: continuation of discussion on CLH as needed.

Friday 28 September: Morning Session
Item 7 – CLH

7.4 General CLH issues
   a. State of play of the submitted CLH dossiers
b. Review of the process for developing CLH opinions

*Optional* – 7.1 CLH Dossiers for discussion and possible adoption: continuation of discussion on CLH dossiers for adoption as needed.

7.3 Appointment of RAC (co-) rapporteurs for CLH dossiers

Item 8 – Restrictions
8.3 Appointment of RAC (co-) rapporteurs for restrictions dossiers

Item 9 – Authorisation
9.1 Appointment of RAC rapporteurs for substances listed in Annex XIV *(if relevant)*

*Optional* – Item 6 – Requests under Article 77 (3)(c): continuation of the discussion if needed
6.1 Gallium arsenide

Item 13 – Main conclusions and Action Points of RAC-18

Item 10 – Guidance issues
10.1 Feedback from guidance consultations
10.2 Report on other guidance activities

Item 12 – Any other business